- Trial phase
- Phase 3
- Time to market
- Unknown. Zimberelimab is investigational in the US with no FDA submission or PDUFA date identified. The drug is furthest along in combination with domvanalimab, but no regulatory filing has been announced. If pivotal data from the completed Phase 3 STAR-221 trial supports a filing, a BLA submission could come in 2027 at the earliest, with potential approval in 2028-2029.
- Why 4/10
- No single hard, dated binary catalyst (PDUFA or pivotal readout) specifically for zimberelimab is scheduled in the next ~12 months. The drug is an investigational PD-1 backbone used in combination trials; its value is embedded in Arcus' broader pipeline. The completed Phase 3 STAR-221 trial (NCT05568095) has no announced data disclosure date. ImpactScore defaults to 4, zimberelimab is a major pipeline component but lacks an imminent binary event.
Zimberelimab is not a standalone binary catalyst, watch for domvanalimab+zimberelimab combination data readouts from the completed Phase 3 STAR-221 (NCT05568095) and the ongoing EDGE-Gastric study. RCUS recently completed a dilutive $250M offering at $17.50/share; monitor Q3 2026 earnings (Oct 26 or Nov 10) for cash runway updates and pipeline progress.
Price Chart
Executive Summary
Zimberelimab (also known as GLS-010 and AB122) is a fully human anti-PD-1 monoclonal antibody being developed by Arcus Biosciences (NYSE: RCUS) as the backbone immunotherapy in its combination pipeline. It works like Keytruda or Opdivo, blocking the PD-1 checkpoint to help the immune system attack cancer cells. The drug is investigational in the US and has no FDA approval or pending PDUFA date. It is primarily studied in combination with Arcus' anti-TIGIT antibody domvanalimab across multiple Phase 2 and Phase 3 trials in non-small cell lung cancer, upper GI tract cancers, and gastric cancer. A Phase 3 trial (NCT05568095) of domvanalimab + zimberelimab + chemo in upper GI adenocarcinoma completed in August 2026. Zimberelimab is a key pipeline asset but not a standalone binary catalyst for RCUS; the stock's near-term moves are more tied to combination data readouts and the casdatifan program.
How It Works
Zimberelimab is a PD-1 checkpoint inhibitor, a type of immunotherapy that works by blocking the 'off switch' on immune T cells. Many cancer cells exploit the PD-1 pathway to hide from the immune system. By blocking PD-1, zimberelimab 'releases the brakes' on T cells, allowing them to recognize and attack tumors. It is a fully human monoclonal antibody (IgG4 type), meaning it is a lab-made protein designed to mimic a natural human antibody, reducing the risk of immune rejection. It is administered intravenously and is similar in mechanism to approved drugs like Keytruda (pembrolizumab) and Opdivo (nivolumab).
Trial Status
Zimberelimab is being studied primarily in combination with domvanalimab (anti-TIGIT) across multiple indications. A Phase 3 trial (NCT05568095, STAR-221) of domvanalimab + zimberelimab + chemotherapy in advanced upper GI tract adenocarcinoma completed in August 2026 with 1,040 patients enrolled. A Phase 2 trial (NCT04736173) in NSCLC completed in September 2026. The Phase 2 EDGE-Gastric study (NCT05329766) in upper GI malignancies is active but not recruiting, with primary completion estimated January 2027. Additional Phase 2 studies in NSCLC (NCT04262856) have completed. Gilead Sciences is also running a Phase 2 trial (NCT06727565) in head and neck squamous cell carcinoma. Results have been published in Nature and ASCO journals showing promising anti-tumor activity.
The Two-Sided Case
Upcoming Catalysts
- Data readout from completed Phase 3 STAR-221 trial (NCT05568095) of domvanalimab + zimberelimab in upper GI cancers, results pending disclosure
- Primary completion of Phase 2 EDGE-Gastric study (NCT05329766) estimated January 2027
- Q3 2026 earnings report (Oct 26 or Nov 10, 2026), cash runway and pipeline update
- Potential regulatory strategy announcement for domvanalimab + zimberelimab combination
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Arcus Biosciences, Inc. 8-K RCUS ·Originating report